3S Pharmaceutical Group China

3SBio is a fully-integrated biotechnology company in China with commercial and R&D programs in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology, and seeking in-licensing opportunity of novel therapies and technologies.

3SBio is actively pursuing international expansion through acquisitions, licensing and strategic partnerships. Please visit www.3sbio.com for more information.

We look forward to having opportunity to discuss potential collaboration with you.

Zhao Peng
Senior BD Manager 

abbisko China

Foucus on R&D Small moleculer anti oncology and inmuno-oncology.
Website:
abbisko.com
Company Size (Fulltime employees)
Please specify your partnering goal
no
Headquartner in China
xiaoyi wu
BDAD 

Bayer Healthcare China

Bayer Healthcare
Dr. Min Pang
Alliance Manager 

BeiGene China

A Biopharma company, looking for license in opportunities.
Website:
Www.BeiGene.com
Company Size (Fulltime employees)
Year of foundation
10
Please specify your partnering goal
Partner
Headquartner in China
Ms. Yan Liu
Vice president 
Functionality

Beijing Continent Pharmaceutical Co., Ltd. China

A private pharmaceutical company,headquartered in Beijing,focus on the research, development,manufacture and marketing of drug products for the treatment of organ fibrosis diseases and other related diseases.

Qin Li
Associate Director,Business Development 

BioPegasus, LLC United States

BioPegasus, LLC specializes in a cost-effective and robust post-proteomics and post-protein and peptide array technology biomarker and target discovery technology platform. This proprietary platform is unique and transformative, allowing systematic, thorough and unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time. It aims to accelerate novel therapeutic and diagnostic development for some devastating diseases to improve our health and quality of life. These diseases include autoimmune diseases, cancer, and, in particular, Alzheimer’s disease.

BioPegasus' technology platform provides a revolutionary tool for systematical and thorough studying novel molecular interactions and mechanism of actions with any molecule of interest. The platform can be used to provide contract services with royalty payment potential to research institutions and companies in IVD, biotech and pharma sectors. The technology can also be packaged into commercial product(s) with a user manual for sale in the market world-wide.

BioPegasus currently is operated by its founder looking for an investor(s), partner(s), and sponsor(s)/client(s) or any form of collaboration/interest.

Website:
not available
Company Size (Fulltime employees)
Year of foundation
2006
Please specify your partnering goal
1) Seeking investment(s) for developing cost-effective and minimally invasive blood antibody biomarker tests for Alzheimer’s disease diagnosis and early detection (a 3-year project); and/or 2) Looking for any interested party(ies) to work together.
Headquartner in China
Assets Information 1
biomarker and target discovery technology platform|||
Biotech/Pharma Asset Stage
Your Research Tool and Service name
A unique and transformative λ phage cDNA expression library construction and screening (not phage display). A cost-effective and robust novel biomarker and target discovery technology platform for novel diagnostic and therapeutic development.
Service Description
BioPegasus' technology platform provides a revolutionary tool for systematically and thoroughly studying novel molecular interactions and mechanism of actions with any molecule of interest and allowing unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time in novel diagnostic and therapeutic development.
Target client type
1) As diagnostic and early detection tests for Alzheimer's disease: general population for early detection (POCT, age 50 years and better) and patients for severity and diagnosis (lab tests); 2) As a research tool: client types include research institutions and diagnostic IVD, biotech and pharma companies
Slides Deck
(pdf, 957.61KB)
Dr. Tianlin Ma
Founder 
Functionality

bright-gene China

R&D attributed company
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
wei alex
manager 

chbd China

chbd
Website:
www.chbd.net
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
奎 汪
常务副会长 

China医药创新促进会 China

China医药创新促进会(原名“China医药工业科研开发促进会”,简称“China药促会”),英文名称:China Pharmaceutical Innovation and Research Development Association(PhIRDA),成立于1988年,是经国家民政部登记注册的非营利性全国性4A级社会组织。
China药促会秉承“创新、产业化、国际化”的宗旨,以临床需求为导向,长期致力于“产学研用资”紧密结合,促进医药行业创新发展,已经成为集医药创新研发型企业、科研机构、临床研究机构、创新服务机构和医药投资机构所组成的医药创新产业化促进平台,目前有会员单位144家。China药促会已成立了药物研发专业委员会、药物临床研究专业委员会、医药政策专业委员会、医药创新投资专业委员会和创新研发服务专业委员会,形成了以创新为核心,以促进创新为目标的涵盖药物研发、生产、使用以及投融资的全链条组织构架,并作为国际药品制造商协会联合会(IFPMA)的成员继续拓展国际交流渠道。
根 李
国际部项目主管